Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Rationale Ayahuasca is a South American psychoactive beverage that contains the naturally occurring psychedelic agent N,N-dimethyltryptamine (DMT). This "tea" has been used for centuries in religious and medicinal contexts in the rain forest areas of South America and is presently gaining the attention of psychedelic users in North America and Europe. Objectives In the present study, the psychological effects and tolerability of ayvahuasca were assessed. Methods Three increasing doses of encapsulated freeze-dried ayahuasca (0.5, 0.75, and 1.0 mg DMT/kg body weight) were administered to six healthy male volunteers with prior experience in the use of this tea, in a single-blind crossover placebo-controlled clinical trial. Results Ayahuasca produced significant dose-dependent increases in five of the six subscales of the Hallucinogen Rating Scale, in the LSD, MBG, and A scales of the Addiction Research Center Inventory, and in the "liking", "good effects" and "high" visual analogue scales. Psychological effects were first noted after 30-60 min, peaked between 60-120 min, and were resolved by 240 min. The tea was well tolerated from a cardiovascular point of view, with a trend toward increase for systolic blood pressure. Modified physical sensations and nausea were the most frequently reported somatic-dysphoric effects. The overall experience was regarded as pleasant and satisfactory by five of the six volunteers, while one volunteer experienced an intensely dysphoric reaction wi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ayahuasca has been demonstrated to be safe in naturalistic (35, 108) and clinical settings, across varying dosages and multiple administrations (26, 109–112).”
From Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol (2025) · cites this paper as [109]
In the citing paper
“Ayahuasca was found to significantly raise the systolic and diastolic blood pressure by 35 Hgmm and the pulse rate by 26 bpm in a 2 min time interval while the rate of increase declines upon repeated intake (Riba et al., 2001).”
From The therapeutic potentials of Ayahuasca: possible effects against various diseases of civilization (2016) · cites this paper as Riba et al., 2001
Citations
Cites
(1970) · Cited by 24,983
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“…and cognitive modifications induced by these agents, as in another study psilocybin's subjective effects were found to be increased rather than reverted by the D 2 receptor antagonist, haloperidol , while they were effectively counteracted by ketanserin and risperidone (Vollenweider et al. 1998).”
BackgroundLane, R. D., Reiman, E. M., Axelrod, B., Yun, L.-S., Holmes, A., & Schwartz, G. E. (1998) · Journal of Cognitive Neuroscience · doi:10.1162/089892998562924 · Cited by 671
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
AGHAJANIAN, G. K., & MAREK, G. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00051-8 · Cited by 514
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444 · cited 1×
“…revealed patterns of increased metabolism throughout the brain, and more specifically in the prefrontal cortices, particularly in the right hemisphere, in healthy volunteers after dosing with psilocybin (Vollenweider et al. 1997; Gouzoulis- Mayfrank et al. 1999b) and mescaline (Hermle et al. 1992).”
BackgroundSerotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors
Pazos, A., Probst, A., & Palacios, J. M. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90326-5 · Cited by 436
McKenna, D. J., Towers, G. H. N., & Abbott, F. (1984) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(84)90003-5 · Cited by 398 · cited 8×
“When compared with IV DMT, it is reasonable to assume that the reversible MAO-inhibiting properties of harmine and harmaline leads to a transient increase in endogenous monoamines, in addition to DMT's own cardiovascular effects.”
BackgroundMethodResultInfluentialHuman psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil.
GROB, C. S., McKENNA, D. J., CALLAWAY, J. C., BRITO, G. S., NEVES, E. S., OBERLAENDER, G., SAIDE, O. L., LABIGALINI, E., TACLA, C., MIRANDA, C. T., et al. (1996) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199602000-00004 · Cited by 338
Self-citationStrassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020009001 · Cited by 291
Human psychopharmacology of N,N-dimethyltryptamine
Strassman, R. J. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00081-2 · Cited by 261 · cited 2×
“The interaction with the 5-HT 1A site has recently been argued to modulate the intensity of the psychedelic experience ( Strassman 1996 ).”
BackgroundThe Botany and Chemistry of Hallucinogens
Reynolds, T., Schultes, R. E., & Hofmann, A. (1974) · Kew Bulletin · doi:10.2307/4108565 · Cited by 255
Visionary Vine: Hallucinogenic Healing in the Peruvian Amazon
de Ríos, M. D. (1972) · Medical Entomology and Zoology · Cited by 219
Gouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219
Hermle, L., Fünfgeld, M., Oepen, G., Botsch, H., Borchardt, D., Gouzoulis, E., Fehrenbach, R. A., & Spitzer, M. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90059-9 · Cited by 182
“Ayahuasca,” the South American hallucinogenic drink: An ethnobotanical and chemical investigation
Rivier, L., & Lindgren, J.-E. (1972) · Economic Botany · doi:10.1007/bf02860772 · Cited by 173
Callaway, J. C., Raymon, L. P., Hearn, W. L., McKenna, D. J., Grob, C. S., Brito, G. S., & Mash, D. C. (1996) · Journal of Analytical Toxicology · doi:10.1093/jat/20.6.492 · Cited by 160 · cited 5×
“The DMT concentration found in the tea was similar to that reported previously for a sample of Daime (Liwszyc et al. 1992) and several Peruvian ayahuasca samples (McKenna et al. 1984), and twice as great as the amount reported for a sample of Hoasca from the Brazilian church União do Vegetal (Callaway et al. 1996).”
BackgroundMethodResultInfluentialSelf-citationGouzoulis‐Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H. J., Kovar, K. ‐., Lindenblatt, H., Hermle, L., Spitzer, M., & Sass, H. (1999) · Psychopharmacology · doi:10.1007/s002130050860 · Cited by 157
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
Pierce, P. A., & Peroutka, S. J. (1989) · Psychopharmacology · doi:10.1007/bf00443425 · Cited by 152
Pharmahuasca: Human Pharmacology of Oral DMT Plus Harmine
Ott, J. (1999) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1999.10471741 · Cited by 140
Callaway, J. C., & Grob, C. S. (1998) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1998.10399712 · Cited by 135
Self-citationMarek, G. J., & Aghajanian, G. K. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00036-5 · Cited by 94
Psychometric assessment of the Hallucinogen Rating Scale☆
Riba, J., Rodrı́guez-Fornells, A., Strassman, R. J., & Barbanoj, M. J. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)00175-7 · Cited by 88
Self-citationPlatelet serotonin uptake sites increased in drinkers ofayahuasca
Callaway, J. C., Airaksinen, M. M., McKenna, D. J., Brito, G. S., & Grob, C. S. (1994) · Psychopharmacology · doi:10.1007/bf02245347 · Cited by 81
Self-citationDifferential interactions of dimethyltryptamine (DMT) with 5-HT1A and 5-HT2 receptors
Deliganis, A. V., Pierce, P. A., & Peroutka, S. J. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90178-8 · Cited by 73
Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI)
Lamas, X., Farré, M., Llorente, M., & Camı́, J. (1994) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)90075-2 · Cited by 55
Plantas de los dioses : orígenes del uso de los alucinógenos
Schultes, R. E., & Hofmann, A. (1982) · Fondo de Cultura Económica eBooks · Cited by 50
Suzuki, O., Katsumata, Y., & Masakazu, O. (1981) · Biochemical Pharmacology · doi:10.1016/0006-2952(81)90320-8 · Cited by 47
Indoleamine and the phenethylamine hallucinogens: mechanisms of psychotomimetic action
Marek, G. J., & Aghajanian, G. K. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00076-3 · Cited by 40
Daime — a ritual herbal potion
Liwszyc, G. E., Vuori, E., Rasanen, I., & Issakainen, J. (1992) · Journal of Ethnopharmacology · doi:10.1016/0378-8741(92)90065-y · Cited by 16
Cited by
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Osório, F. D. L., Sanches, R. F., Macedo, L. R., dos Santos, R. G., Maia-de-Oliveira, J. P., Wichert-Ana, L., de Araujo, D. B., Riba, J., Crippa, J. A., & Hallak, J. E. (2015) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2014-1496 · Cited by 488
Self-citationPalhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049882 · Cited by 390
Self-citation
Metadata
- Authors
- Riba, J., Rodríguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, M., Callaway, J. C., & Barbanoj, M. J.
- Affiliations
- Hospital de Sant Pau (ES)
- University of Eastern Finland (FI)
- Venue
- Psychopharmacology
- Published
- 2001-02-22
- Volume
- 154
- Issue
- 1
- Pages
- 85-95
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2036881116
- Cited by
- 303
- References
- 31
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 15 · 2023: 22 · 2022: 35 · 2021: 24 · 2020: 20 · 2019: 12 · 2018: 13 · 2017: 18 · 2016: 14 · 2015: 15 · 2014: 8 · 2013: 8 · 2012: 15
- FWCI
- 6.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- ayahuasca, N,N-dimethyltryptamine, DMT, psychedelic effects, subjective experience, tolerability, dose-response relationship, Addiction Research Center Inventory, cardiovascular effects, nausea, healthy volunteers
- MeSH terms
- Adult, N,N-Dimethyltryptamine, Hallucinogens, Hemodynamics, Humans, Male, Plant Extracts, Plants, South America, Single-Blind Method
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.